BYSI BeyondSpring

BeyondSpring to Host First-Quarter 2018 Financial Results Conference Call on June 21, 2018

BeyondSpring to Host First-Quarter 2018 Financial Results Conference Call on June 21, 2018

NEW YORK, June 18, 2018 (GLOBE NEWSWIRE) -- . (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that the Company will report first-quarter 2018 financial results on Thursday, June 21, 2018. BeyondSpring’s management team will host a conference call and webcast at 8:00 a.m. Eastern Time on Thursday, June 21, 2018, to discuss the financial results and provide an operational update.

The conference call may be accessed by dialing (866) 362-6591 (U.S.) or (706) 758-3199 (international) and referencing conference ID 3398418. A live webcast will be available on the Investors page of the Company's website at . An archived replay of the webcast will be available for 30 days.

About BeyondSpring

BeyondSpring is a global, clinical-stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with University of Washington in de novo drug discovery using ubiquitination platform. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and two Phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has a seasoned management team with many years of experience bringing drugs to the global market.

Contact:

Investor Relations:

Laura Perry or Joe Rayne

Argot Partners

212.600.1902

EN
18/06/2018

Underlying

BYSIBeyondSpring

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BeyondSpring

 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabu...

BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer FLORHAM PARK, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that the first patient has been dosed in a Phase 2 investigator-initiated trial (IIT) with Pembrolizumab, Plinabulin, BeyondSpring’s lead asset, plus Etoposide/Platinum (EP) for f...

March 25, 2024 1 EN
 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Peri...

BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements FLORHAM PARK, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced that on February 20, 2024, the Company received a written notification on minimum bid price compliance (the “Notification Letter”) from The Nasdaq ...

February 26, 2024 1 EN
 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing ...

BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K NEW YORK, Jan. 10, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced that on January 4, 2024, it received a Foreign Delinquency Compliance Plan Alert Letter (the “Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”). In the Letter, the...

January 10, 2024 1 EN
 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requir...

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements NEW YORK, Dec. 18, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced that on December 14, 2023, it received a written notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the requirement to maintai...

December 18, 2023 1 EN
 PRESS RELEASE
Free
BYSI BEYONDSPRING

BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC...

BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitors New Clinical Data from MD Anderson Presented at the Society for Immunotherapy of Cancer’s 38th Annual Meeting80% DCR (disease control rate) in non-radiated tumor with Durable Responses in Heavily Pretreated Patients in 6 different cancersFull data was presented at SITC’s 38th Annual Meeting; The Company will host a call at 8:30 a.m. ET to...

November 7, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch